ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Domestic Enterprises Have Fully Laid out the Blue Ocean of US$10 Billion, and CAR-T Therapy Must Overcome the Achilles' Heel of Solid Tumor
August 07, 2023The solid tumor is one of the two most deeply developed fields in CAR-T therapy, thus it is extremely urgent to overcome solid tumor in CAR-T therapy, considering domestic market access policy and current biomedical capital environment. -
IASO, Innovent CART-cell Therapy Gets Orphan Designation
February 14, 2022anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma. -
Bristol Myers Squibb and bluebird bio get US FDA nod for Abecma (idecabtagene vicleucel) to treat relapsed or refractory multiple myeloma
March 29, 2021Abecma is a first-in-class BCMA-directed personalised immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple myeloma. -
Ide-cel provides lasting remissions in multiply-relapsed myeloma
February 26, 2021BMS and bluebird bio have applied to the FDA for approval of ide-cel as a standard therapy for relapsed or refractory multiple myeloma based on positive Phase II trial results. -
SpringWorks Therapeutics in pact with Janssen to assess Nirogacestat with Teclistamab in patients with relapsed or refractory multiple myeloma
September 15, 2020Third collaboration to evaluate nirogacestat in combination with BCMA therapies across modalities.
Pharma Sources Insight January 2025
